Monitoring Recombinant Factor VIIa Treatment: Efficacy Depends on High Levels of Fibrinogen in a Model of Severe Dilutional Coagulopathy

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts

“…Importantly, combined administration of rFVIIa and fibrinogen provided a synergistic effect on WB clot formation resulting in profiles similar to those obtained from healthy controls, and a significant improvement in all haemostatic characteristics of clot formation, even at very low platelet counts. The advantages of combining rFVIIa and fibrinogen observed in our study corroborates well with previous in vitro findings in other patient groups (Ganter et al , ; Tanaka et al , ; Fenger‐Eriksen et al , ; Sorensen et al , ).…”

The use of thromboelastography, thrombin generation test and clotting tests to evaluate the efficacy of hemostatic therapy with recombinant activated factor VII in hemophilia patients with inhibitor

“…В то же время в многоцентровом исследовании введение rFVIIa в дозе 90 мкг/кг, т. е. в той же дозе, что и в нашем ис-следовании, проводило к нормализации параметров ТЭГ у больных с ингибиторной формой гемофилии [13]. Поэтому ТЭГ в настоящее время является од-ним из наиболее принятых методов мониторинга те-рапии rFVIIa у пациентов с ингибиторной формой гемофилии [9,13,14]. Использование ТЭГ позволяет не только мониторировать терапию шунтирующими препаратами, но и выявлять резистентность к одно-му из них, вовремя изменить тактику гемостатиче-ской терапии, индивидуализировать лечение [6,15].…”

Effects of High Dose Fibrinogen on in vitro Haemodilution with Different Therapeutic Fluids

“…Still, evidence of it's worth is mounting, [24] and some suggest that complementary use of TEG and Sonoclot is viable. In effect, parallel use of the devices has already been applied in a research setting [6].…”

“…fibrinogen or a combination with fibrinogen + prothrombin complex concentrate or factor XIII have been successfully monitored with ROTEM/TEG. [4,5] A joint study of fibrinogen and recombinant factor VIIa treatment of dilutive coagulopathy has been performed on the Sonoclot, [6] but the field is lacking additional recent studies.…”